Description
+ Include: 28 videos + 36 pdfs, size: 16.2 GB
+ Target Audience: hematologist, immunologist, internist, oncologist, critical care physician
+ Sample video: contact me for sample video
+ Information:
Friday, April 28, 2023, 9:00 AM – Saturday, April 29, 2023, 1:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY
This 3rd international Symposium will bring together a diverse group of experts and thought leaders in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss current advances in the field, mechanisms of toxicities, symptom burden, and late effects after HCT and cellular therapies along with best practices to prevent and treat these complications.
This unique 2-day program will be comprised of sessions dedicated to a wide range of pre-clinical, translational, and clinical topics, including cellular therapies as a model of accelerated aging, CAR T cell-related toxicities, infectious complications, decision science, the role of the gut microbiome in toxicities, debates on how to diagnose and treat difficult complications such as transplant-associated thrombotic microangiopathy, and several keynote lectures from world experts.
>> Who Should Attend
The target audience for this Symposium includes physicians, advanced practice providers (physician assistants and nurse practitioners), and nurses who treat or refer patients for hematopoietic cell transplantation or immune effector cell therapies (i.e., CAR T cells; tumor infiltrating lymphocytes, or T cell receptor therapy).
Available to in-person attendees only, the focus of this optional luncheon session is on Improving Outcomes with Active Acute Leukemia Undergoing Transplant — Do We Need to Reinduce Patients With Active AML?
Due to space, the luncheon is only available to 50 attendees and selection must be made during course registration. We do recommend early registration in order to secure your spot. Luncheon confirmation will be sent prior to the start of the Symposium.
We are pleased to invite the submission of abstracts for this Symposium. Abstracts will be selected on the basis of their scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and/or clinical research in progress will be accepted.
- Identify the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.
- Discuss the best practices in the prevention and treatment of toxicities and symptom burden after HCT and cellular therapy.
- Collaborate with a multidisciplinary group of colleagues to discuss, brainstorm, and plan future quality improvement and research efforts to reduce toxicities, improve the patient experience, and decrease non-relapse mortality.
+ Topics:
A New, but Familiar Foe- IEC-HS (HLH).mp4
A New, but Familiar Foe- IEC-HS (HLH).pdf
Abstracts Biopsy proven kidney specific-thrombotic microangiopathy without systemic markers of hemolysis in patients with chronic kidney disease.pdf
Abstracts CAR T-Associated Infection- A Single-Center, Five-Year Retrospective.pdf
Abstracts Connected Care Remote Monitoring after Discharge from Inpatient Autologous or Allogeneic Stem Cell Transplant.pdf
Abstracts Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD.pdf
Abstracts Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy- a pharmacovigilance analysis of the FDA reporting system.pdf
Abstracts Encouraging Outcomes after Second Hematopoietic Cell Transplants with Unrelated Cord Blood Grafts for Post-Transplant Relapse in Pediatric Patients.pdf
Abstracts Free interleukin-18 is elevated in CD22 CAR T-cell associated hemophagocytic lymphohistiocytosis-like toxicities.pdf
Abstracts Intrathecal Hydrocortisone for Treatment of Children and Young Adults with CAR T-cell Immune-Effector Cell Associated Neurotoxicity Syndrome.pdf
Abstracts Successful incorporation of electronic patient reported outcomes using PROMIS-29 into standard of care after hematopoietic stem cell transplant.pdf
Adoption or De-adoption of Evidence Into Practice in Transplantation and Cellular Therapy.mp4
Adoption or De-adoption of Evidence Into Practice in Transplantation and Cellular Therapy.pdf
Biomarkers of Aging in BMT and Next Steps in Our Field.mp4
Biomarkers of Aging in BMT and Next Steps in Our Field.pdf
Blocking IFN- Enhancement of CAR T cell Proliferation Without Increasing CRS.pdf
CAR T Toxicities Panel Discussion Q&A.mp4
CAR-HEMATOTOX- Prolonged Cytopenias After CAR T cell Therapy.mp4
CAR-HEMATOTOX- Prolonged Cytopenias After CAR T cell Therapy.pdf
Cellular Therapies as a Model of Accelerated Aging Panel Discussion Q&A.mp4
CMV in the Lung- Pathogen, Paradigm, Puzzle.mp4
CMV in the Lung- Pathogen, Paradigm, Puzzle.pdf
Cognitive Impacts of Accelerated Aging in BMT.mp4
Cognitive Impacts of Accelerated Aging in BMT.pdf
Decision Science and Toxicities Panel Discussion Q&A.mp4
FMT as Prophylactic Supportive Care.mp4
FMT as Prophylactic Supportive Care.pdf
FMT for Treatment of Acute GVHD.mp4
FMT for Treatment of Acute GVHD.pdf
Harmonization of Toxicity Definitions – Challenges – Process and Example.mp4
Harmonization of Toxicity Definitions – Challenges – Process and Example.pdf
HHV-6 Reactivation and Related Complications After HCT and CAR-T cell Therapies.pdf
Immune Aging and Senolytics.mp4
Immune Aging and Senolytics.pdf
Incorporating Patient Reported Outcomes Into Standard of Care Practice.mp4
Incorporating Patient Reported Outcomes Into Standard of Care Practice.pdf
Infections as Toxicities Panel Discussions Q&A.mp4
Integrating Patient Values and Preferences Into Treatment Decision Making.mp4
Integrating Patient Values and Preferences Into Treatment Decision Making.pdf
MSKTox2023_Brochure.pdf
Nutrition and Microbiota in Allo-HCT.mp4
Nutrition and Microbiota in Allo-HCT.pdf
Nutrition – Microbiome and Toxicities Panel Discussion Q&A.mp4
Nutritional Interventional Trial to Improve the Mircrobiome and Prevent Acute GVHD.mp4
Nutritional Interventional Trial to Improve the Mircrobiome and Prevent Acute GVHD.pdf
Parkinsonian Neurotoxicity After BCMA CAR T cells.mp4
Parkinsonian Neurotoxicity After BCMA CAR T cells.pdf
Plant Sequencing and Gut Microbiome in Allo-HCT.pdf
Post CAR T Cell Infections.mp4
Post CAR T Cell Infections.pdf
Pulmonary Toxicities of Cellular Therapies.mp4
Pulmonary Toxicities of Cellular Therapies.pdf
Remote Performance Status Monitoring Using Wearables and PROs.mp4
Remote Performance Status Monitoring Using Wearables and PROs.pdf
Respiratory Viral Infections- Acute and Persistent Lung Effects.mp4
Respiratory Viral Infections- Acute and Persistent Lung Effects.pdf
Special Luncheon Debate.mp4
Special Luncheon Debate.pdf
Transplant as a Model of Accelerated Aging.mp4
Transplant as a Model of Accelerated Aging.pdf
Updates on the Diagnosis and Treatment of TA-TMA- Discussion with Experts.mp4
Updates on the Diagnosis and Treatment of TA-TMA- Discussion with Experts.pdf
Viral Specific T Cell Therapy for Polyomavirus- Overcoming BK and JC Virus After Cell Therapy.mp4
Viral Specific T Cell Therapy for Polyomavirus- Overcoming BK and JC Virus After Cell Therapy.pdf
Reviews
There are no reviews yet.